08:52 AM EDT, 06/25/2025 (MT Newswires) -- Corvus Pharmaceuticals ( CRVS ) said Wednesday its partner Angel Pharmaceuticals received approval from China's National Medical Products Administration for the clinical trial of soquelitinib, a new treatment for atopic dermatitis.

The phase 1b/2 trial will evaluate once-daily and twice-daily oral dosing of soquelitinib over a 12-week treatment period, the company said.

Each cohort includes patients receiving placebo and escalating doses of soquelitinib, ranging from 100 mg twice daily to 400 mg once daily.

Angel Pharma, which holds rights to develop and commercialize soquelitinib in greater China, will cover all expenses related to its development in China.